Ewing family tumors (EFT), classically Ewing's sarcoma and peripheral primitive neuroectodermal tumor, share a common class of tumor-specific fusion genes thought to be key mediators of tumor biology. Here we demonstrate that the most common Ewing's fusion, EWS/FLI1, produces transcriptional upregulation of GLI1 and its direct transcriptional target PATCHED1 in a model transformation system. This deregulation of GLI1 is common to other EWS/ets chimera and depends on the functional transcriptional regulatory domains. Inhibition of GLI1 via RNAi or via overexpression of endogenous inhibitors results in a reduction of EWS/FLI1 transformation activity. Activation of GLI1 appears to occur in a Hedgehog-independent fashion as blockade of Hedgehog signaling has only a modest effect on EFT cells. We present evidence that EWS/FLI1 upregulation of cMYC may play a role in the upregulation of GLI1 in EWS/ FLI1-transformed NIH3T3 cells. Finally, we demonstrate that observations made in a model transformation system translate to an Ewing cellular background. EFT cell lines express GLI1 and PATCHED and this expression is EWS/FLI1 dependent. Inhibition of GLI1 expression via RNAi results in reduced anchorage-independent growth in an EFT cell line. GLI1 appears to be a transcriptionally deregulated target of EWS/FLI1 that mediates a portion of its tumorigenic phenotype.
Introduction
The Ewing family tumors (EFT) consist of the traditional pathologic categories of Ewing's sarcoma (both bony and extraosseous) and peripheral primitive neuroectodermal tumor. These tumors are largely limited to the first three decades of life and have their greatest incidence in the adolescent years (Pizzo and Poplack, 2005) . They have a high propensity to metastasize and even localized, resected disease requires intensive multiagent chemotherapy to achieve more than minimal rates of cure (Boyer et al., 1967; Bacci et al., 1982) . Occurring in a diverse range of osseous and soft tissue sites, it is one of the few tumors to which no cell of origin can be assigned. Nearly all cases feature a class of chromosomal translocations that fuse the DNA-binding domain of an ets transcription factor to the N-terminal region of the EWS gene (Delattre et al., 1992) . The prototype fusion gene product is EWS/FLI1, which occurs in approximately 85% of cases (Lazar et al., 2006) . These EWS/ets transcription factors are postulated to alter gene expression and centrally mediate tumor phenotype (Janknecht, 2005; Arvand and Denny, 2001) . Many genes whose expression is enhanced or diminished by EWS/FLI1 have been identified (see Janknecht, 2005 for a review), though none of these targets has proven so crucial to tumor biology as to independently predict clinical outcome. With our present state of understanding, these compiled targets comprise an EWS/FLI1 signaling network. Presently unknown but crucially important is the topology of this network. Is the signaling traffic diffusely shared or are there certain critical nodes that determine a host of downstream signaling events?
Such critical nodes may exist in this network, each with a given set of dependencies. The elucidation of such dependencies would permit the construction of a hierarchy of EWS/FLI1 targets. If such a hierarchy can be shown to exist, therapeutic attack directed at more centrally situated members of the hierarchy would likely prove more advantageous than that directed to more peripheral mediators in the process. If such a hierarchy is to be elucidated, it is likely to take the form of a systematic deregulation of an already identified tumorigenic pathway.
Here we provide the first evidence that GLI1, the critical effector of Hedgehog (HH) signaling, is deregulated by EWS/FLI1. This deregulation can be demonstrated in a model transformation system. RNAi-mediated reduction of GLI1 expression reduces EWS/FLI1 transformation. Furthermore, employment of an endogenous suppressor of GLI1 activity likewise produces a reduction of EWS/ FLI1 transformation. We present evidence that this deregulation occurs in an HH-independent fashion and that EWS/FLI1-mediated deregulation of cMYC may play a role in this deregulation. Finally, we demonstrate that this deregulation also applies in an Ewing tumor cellular background.
Results

EWS/FLI1 enhances GLI1 expression in NIH3T3 cells
Prior investigations with EWS/FLI1 deregulation of platelet-derived growth factor C (PDGF-C) (Zwerner and May, 2001 ) directed our attention to evidence in other tumor systems that there could be a link between PDGF pathway deregulation and deregulation of the HH-GLI pathway (Xie et al., 2001; Lokker et al., 2002) . To address this possibility, we investigated whether EWS/FLI1 might act to alter this pathway in an NIH3T3 model transformation system. When overexpressing EWS/FLI1, NIH3T3 demonstrate enhanced anchorage-independent growth and augmented ability to form tumors in immunodeficient mice (May et al., 1993 (May et al., , 1997 . Furthermore, expression of EWS/FLI1 has been shown to confer an altered cellular phenotype that to an extent mirrors that found in Ewing's tumors (Teitell et al., 1999) . Using retroviral expression vectors to derive pure polyclonal cell lines, we used northern blot to assess the state of signaling via this pathway. Figure 1a demonstrates that EWS/FLI induces augmented levels of GLI1 and Figure 1b shows that the direct target of GLI1, PATCHED1 (Alexandre et al., 1996; Marigo et al., 1996; Hepker et al., 1997) , is also upregulated. Figure 1c demonstrates that levels of GLI1 protein correlate with this transcriptional upregulation. Attempts to confirm these findings with Gli1 reporter assays were complicated by nonspecific reporter suppression by EWS/FLI1, as is detail in the online Supplementary data. So, EWS/FLI1 acts to enhance GLI1 expression with the concurrent upregulation of PATCHED1 indicating intact signaling downstream of GLI1.
The oncogenic HH species Sonic Hedgehog (SHH) and Indian Hedgehog are expressed at very low levels and are not upregulated by EWS/FLI1 (data not shown), suggesting an HH-independent mechanism. Since both GLI2 and GLI3 have been shown to upregulate GLI1 (Dai et al., 1999) , we assessed the expression of these forms and found that EWS/FLI1 upregulates neither (data not shown).
Several distinct EWS/ets chimera are associated with clinical EFT. Since these chimera produce similar clinical disease, genes deregulated by more than one of these chimera can be assumed to be more likely to have biologic significance. As can be seen in Figure 1d (right), three different EWS/ets chimera associated with EFT (EWS/FLI1, EWS/ERG and EWS/ETV1) produce HH-GLI deregulation as assessed via PATCHED1 expression. The same deregulation is demonstrated with the artificial chimera TLS/FLI that has been found to deregulate other EWS/ets targets (Braun et al., 1995) .
Since EWS/FLI1 has been shown to transform by means that are both dependent and independent of intact DNA binding (Jaishankar et al., 1999; Welford et al., 2001) , we assessed the role of EWS/FLI1 functional moieties on pathway deregulation. Alternate forms of EWS/ets chimera produce similar deregulation of GLI1 signaling (d, left) . (d, right) shows that GLI1 signaling depends on both the transactivation domain (del 22) and the DNA-binding domain (del Ets) of EWS/FLI1. Unrelated transforming genes such as activated n-RAS do not deregulate GLI1 though cMYC does in this cellular background. The two parts of (d) were part of the same gel and were blotted, hybridized and exposed together. They were cut to ensure ease of handling.
those lacking the ets DNA-binding domain (del Ets). These findings are consistent with HH-GLI pathway activation requiring EWS/FLI1-mediated transcriptional activity. To assess the specificity of this deregulation, we assessed the pathway status with two other agents known to transform NIH3T3. Figure 1d further demonstrates that PATCHED1 is not deregulated by activated n-RAS, which is also known to transform NIH3T3. However, we do find that cMYC overexpression does appear to deregulate this pathway.
GLI1 contributes to EWS/FLI1-mediated transformation of NIH3T3 cells
We next aimed to determine if the observed deregulation of GLI1 is of biologic importance in EWS/FLI1 transformation. As a means of specifically inhibiting GLI1 signaling, we constructed an shRNA directed to GLI1 (Gli1-687-hp, see 'Materials and methods') into the shRNA vector pSuper (Brummelkamp et al., 2002) .
To demonstrate its effects, we transiently transfected this construct into NIH3T3 cells along with an EWS/ FLI1 expression vector. As shown in Figure 2a , western blot analysis indicates that this construct is effective at reducing the levels of GLI1 protein in NIH3T3 coexpressing EWS/FLI1 in a transient transfection assay. Next, to determine the biologic relevance of this reduction, NIH3T3 cells were stably transfected with the pSuper shRNA construct or a vector control with a hygromycin selectable marker. A polyclonal population of stable integrants was selected for both the hairpin and pSuper control and both populations appeared to propagate similarly. These populations were then each infected with EWS/FLI1 recombinant retrovirus and antibiotic selected with G418. These EWS/FLI1-expressing cell populations were plated in soft agar. As shown in Figure 2b , colony-forming efficiency was diminished by GLI1 shRNA. Histograms in Figure 2b summarize the results of several experiments with both the 687-Gli1-hp and a separately targeting Gli1-2757-hp using retroviral shRNA vectors and a luciferase hairpin control.
RNAi methods are inevitably plagued with questions of possible off-target effects leading to a false phenotype. We sought to further validate our RNAi results via a wholly unrelated methodology. The activity of GLI1 is tightly controlled by a number of endogenous regulatory factors including Suppressor of Fused (SUFU). SUFU has been shown to act to suppress GLI1 signaling both by blockade of GLI1 transcriptional activation at target promoters and by encouraging cytoplasmic sequestration of the GLI1 transcription factor (Kogerman et al., 1999; Cheng and Bishop, 2002) . SUFU is expressed in NIH3T3 cells and its expression is not modulated by EWS/FLI1 (data not shown). We hypothesized that overexpression of SUFU could be used to suppress GLI1 activity. If GLI1 activity is as important to EWS/FLI1 biology as our RNAi experiments indicate, overexpression of SUFU would be expected to diminish EWS/FLI1 biologic activity. To test this hypothesis, we used SUFU recombinant retrovirus to derive polyclonal NIH3T3 lines via antibiotic selection. Control lines were derived in parallel. We then superinfected these cell populations with EWS/FLI1 recombinant retrovirus with another selectable antibiotic marker. When plated in soft agar (Figure 2c ), these lines demonstrated a marked suppression of anchorageindependent growth in those cells expressing SUFU. Figure 2c also shows that SUFU-overexpressing cells are still capable of transformation by a downstream mediator such as PDGF-C. These findings further support our hypothesis and further demonstrate the role of GLI1 in EWS/FLI1.
EWS/FLI1 deregulation of GLI1 is Hedgehog independent
The vast majority of instances in which GLI1 deregulation occurs involve either positive activation by overexpression of HH ligand or the loss of pathway It is ineffective at reducing transformation by platelet-derived growth factor C (PDGF-C), which is also known to transform NIH3T3 independent of EWS/FLI1.
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JP Zwerner et al inhibition by PATCHED. The lack of convincing enhanced or differential expression of HH species in our system suggests that GLI1 activation in EWS/FLI1-transformed NIH3T3 is effected via an HH-independent mechanism. To test this hypothesis, we compared HHactivated NIH3T3 with the same cells transformed with EWS/FLI1. We first assessed the HH responsiveness of NIH3T3 using two means of activating the pathway utilizing the classical mechanism involving the HH/ smoothened (SMO) axis. We retrovirally transduced murine SHH and an activated mutant of SMO into NIH3T3 cells. These antibiotic selected polyclonal lines demonstrate marked upregulation of both GLI1 and PATCHED1 (Figure 3a ).
To further demonstrate the HH responsiveness of these cells, we evaluated the expression of potential HH responsive genes. Figure 3b shows that PDGF-C and BMI-1 are upregulated by HH overexpression.
The upregulation of PDGF-C validates our initial hypothesis that some EWS/FLI1 targets are also HH-GLI1 targets. This finding also demonstrates that HH-GLI signaling can upregulate the PDGF-C ligand in addition to its receptor, PDGFR-a (Xie et al., 2001 ). This also shows that BMI-1 is regulated by aberrant HH-GLI signaling in NIH3T3, as has been observed in the background of cerebellar development and medulloblastoma (Leung et al., 2004) . Even though GLI1 signaling is important to the EWS/FLI1-transformed Figure 3 EWS/FLI1 enhancement of GLI1 signaling is HH independent. Real-time qPCR demonstrates that NIH3T3 overexpressing murine HH or activated smoothened (SMO*) demonstrate dramatic upregulation of GLI1 and PATCHED1 (a). HH targets such as platelet-derived growth factor C (PDGF-C) and BMI-1 are also upregulated by qPCR (b), further demonstrating the HH responsiveness of this cell line. However, HH agonists alone (c) are insufficient to reproduce the EWS/FLI1 phenotype. While cyclopamine can effectively block HH signaling as measured by qPCR in these cells (d), cyclopamine has little effect on GLI1 or PATCHED1 transcript (e) and no effect on Gli1 protein (f) in EWS/FLI1-transformed NIH3T3. Furthermore, the small changes in GLI1 signaling by cyclopamine are ineffective at reducing EWS/FLI1 transformation (g) as are other means of GLI1 suppression. The lighter background with transformed cell lines reflects the color change with media acidification in transformed cells.
EWS/FLI1 deregulates GLI1 JP Zwerner et al phenotype, SHH and SMO* overexpression alone are insufficient to induce enhanced anchorage-independent growth as does EWS/FLI1 (Figure 3c ).
This failure of SHH and SMO to reproduce even a portion of the EWS/FLI1 phenotype further suggests that EWS/FLI1 activation of GLI1 may work via an HH-independent mechanism. To further dissect the mechanisms of GLI1 activation employed the compound cyclopamine, which suppresses HH signaling by suppressing the activation of native SMO (Chen et al., 2002) . Using the same SHH overexpressing NIH3T3 (Figure 3d ), treatment with cyclopamine effects a dramatic reduction in PATCHED1 and GLI1 transcriptional levels seen with HH overexpression.
We then treated EWS/FLI1-transformed NIH3T3 with the same proven-effective concentration of cyclopamine. As shown in Figure 3e , these cells show only a modest downregulation of GLI1, perhaps due to SHH in media in these SHH-sensitive cells (Figure 3e ). Furthermore, we saw no significant downregulation of PATCHED1. Additionally, we saw no significant drop in Gli1 protein on western blot ( Figure 3f ). As might be expected, these modest changes in GLI1 signaling with cyclopamine treatment have no discernable effect on EWS/FLI1 transformation of NIH3T3 cells (Figure 3g ) as do the GLI1-dependent means of pathway blockade we have demonstrated earlier in this paper. So HH activation does not produce phenotypic changes in NIH3T3 cells and pharmacologic blockade of SMO activation has little effect on GLI1 signaling or on the EWS/FLI1-transformed phenotype. This evidence supports an HH-independent mechanism. cMYC may play a role in GLI1 deregulation As noted above (Figure 1 ), cMYC can also deregulate GLI1 signaling in this NIH3T3 system. cMYC has long been known to be upregulated by EWS/FLI1 in some contexts (Bailly et al., 1994; Dauphinot et al., 2001; Hu-Lieskovan et al., 2005b) . Figure 4a shows, that as in these other systems, EWS/FLI1 does lead to upregulation of cMYC in NIH3T3. As the polycomb gene BMI-1 has been shown to be targeted by both HH signaling (Leung et al., 2004) and cMYC (Guney et al., 2006) , we assessed its expression and found that like PATCHED1 and PDGF-C it is an HH-GLI1 target which is also deregulated by EWS/ FLI1 in NIH3T3.
This suggests that EWS/FLI1 may deregulate GLI1 in part via cMYC deregulation. If cMYC is involved in EWS/FLI1 deregulation of GLI-1, then isolated overexpression of cMYC would be predicted to produce similar effects to EWS/FLI1 in upregulating expression of GLI1 and its putative targets PATCHED1 and BMI-1. As shown in Figure 4b , both EWS/FLI1 and cMYC produce enhanced GLI-1 expression. Additionally, putative GLI-1 targets PATCHED1 and BMI-1 are also upregulated by both EWS/FLI1 and cMYC. Taken together, these data preliminarily suggest that EWS/ FLI1 may act in part through cMYC to deregulate HH signaling in NIH3T3.
EWS/FLI1 deregulates GLI1 in Ewing's sarcoma cell lines To assess whether these signaling events in EWS/FLI1-transformed NIH3T3 cells have relevance to Ewing's tumors, we evaluated GLI1 expression in an Ewing's tumor cellular background (Figure 5a ). Using reverse transcription-PCR for GLI1, we were able to confirm levels of GLI1 transcript in several Ewing cell lines. For comparison, we included analysis of two cell lines, SAOS2 and Jurkat, which are in the upper quartile of GLI1 expression in Affymetrix Hu133A microarray data for the NCI-60 panel of cell lines (Novartis, http:// wombat.gnf.org). GLI1 expression in the Ewing lines is comparable or superior to these two lines. GLI1 expression in K562 cells, in the lower quartile of the NCI-60, is appropriately measured below all other lines. For PATCHED1, expression roughly correlates with GLI1 expression in the Ewing cell lines and is again comparable or higher than expression in SAOS2, which is in the upper quartile of PATCHED1 in NCI-60 microarray data.
This documented GLI1 expression is suggestive, but for the NIH3T3 observations to truly bear out, we must demonstrate the dependence of GLI1 expression on EWS/FLI1. To accomplish this we used an EWS/FLI1-targeted siRNA in a system using Ewing cell line xenografts. This system has been previously described (Hu-Lieskovan et al., 2005a) and it employed siRNA directed to the EWS/FLI1 type 1 fusion breakpoint. The 
JP Zwerner et al siRNA was packaged for systemic delivery and was used to reduce EWS/FLI1 expression and to cause a regression in size of tumors already established in immunodeficient mice. This siRNA reagent has been confirmed to reduce expression of EWS/FLI1. We assessed tumor RNA from this system by real-time quantitative PCR (qPCR) and demonstrated reduced expression of both GLI1 and PATCHED1 in specimens with siRNA-induced reduction in EWS/FLI1 expression ( Figure 5b ). These data demonstrate that the increase in GLI1 expression in seen in EWS/FLI1-transformed NIH3T3 cells is also a property of this Ewing tumor cell line. To further corroborate this connection, we drew on the observation that some EFT cell lines express less EWS/FLI1 with longer passage. This led us to hypothesize that EFT cell lines in passage might also be expressing EWS/ets downstream targets at less than maximal levels. Therefore, enhanced expression of EWS/FLI1 via a high-level expression vector could lead to enhanced expression of EWS/FLI1 targets in EFT cell lines. To further test the linkage between EWS/FLI1 and GLI1 expression in EFT cell lines, we transduced two such lines with recombinant retrovirus expressing EWS/FLI1 or a vector control. As seen in Figure 5c , markedly increased levels of EWS/FLI1 transcript could be demonstrated by qPCR in those cells transduced with EWS/FLI1 retrovirus. The result of this enhanced expression of EWS/FLI1 is enhanced expression of both GLI1 and PATCHED1. This experiment further indicates that GLI1 expression in EFT cell lines is dependent on EWS/FLI1 expression. These data agree with findings recently published (in aggregate form) in which RNAi targeting a different region of EWS/FLI1 was used in another Ewing cell line (Smith et al., 2006) . In that study, GLI1 was among the genes whose expression was both diminished by EWS/FLI1 RNAi and restored by reexpression of EWS/FLI1.
GLI1 is significant to Ewing tumor cell line phenotype
To assess whether EWS/FLI1-mediated overexpression of GLI1 is also significant to EFT cell line phenotype, we used the same shRNA targeting sequences described above in an EFT cell line. The selected stable polyclonal populations appeared to propagate equivalently. As shown in Figure 6a , stable transfection of GLI1 shRNA decreases expression of GLI1 transcript in the EFT cell line TC32. There is also concomitant reduction in the GLI1 target PATCHED1, indicating that the expected reduction in GLI1-mediated signaling. The reduction in GLI1 expression using an alternative targeting sequence (GLI-2757, see 'Materials and methods') is identical. The effects of this shRNA-induced reduction of GLI1 expression are shown in Figure 6b , in which either targeting sequence significantly reduces anchorageindependent growth in TC32. These data demonstrate that the observations originally made in the NIH3T3 model transformation system translate to an Ewing's sarcoma cell line background. They indicate that GLI1 is an EWS/FLI1 target of biologic significance in EFT.
Discussion
Here we have demonstrated that EWS/FLI1 induces enhanced expression of GLI1 transcript and the GLI1 target PATCHED1. This upregulation appears to rely on EWS/FLI1 acting as a transcription factor with intact DNA-binding and transcriptional activation domains. EWS/FLI1-mediated upregulation of cMYC appears to contribute to this upregulation. GLI1 upregulation appears to be important to the NIH3T3-transforming capability of EWS/FLI1 in that both RNAi directed to GLI1 and overexpression of the HH pathway inhibitor SUFU result in a diminution of the EWS/FLI1-transformed phenotype. EWS/FLI1 upregulation of GLI1 appears to be largely independent of HH species in that HH species are not upregulated by EWS/ FLI1 and cyclopamine treatment of NIH3T3 cells results in only a modest diminution of GLI1 and PATCHED. Finally, these observations made in a model transformation system appear to apply to EFT cell lines. GLI1 transcript and protein are present in significant levels in EFT cell lines. Inhibition of EWS/ FLI1 by RNAi results in decreased GLI1 and PATCHED1 expression. Furthermore, enforced overexpression of EWS/FLI1 in heavily passaged EFT cell lines results in enhanced expression of GLI1 and of its transcriptional target PATCHED1. Finally, shRNAmediated reduction in GLI1 is sufficient to reduce the capacity of an EFT cell line for anchorage-independent growth.
The involvement of HH or GLI1 in cancer is well established (Kasper et al., 2006) . In sarcomas in adults, the grade of tumor has been shown to correlate with the level of GLI1 expression (Stein et al., 1999) . In Ewing's sarcoma, no evidence was found for amplification of GLI1 at the genomic level, but no expression data on Ewing's tumors were documented in this study (Stein et al., 1999) . GLI1 has been shown to be important in maintenance of a stem cell phenotype in a variety of tumor systems Zhou et al., 2006; Anton Aparicio et al., 2007; Clement et al., 2007) . The mechanism of activation of this pathway has largely involved overexpression of an HH ligand or loss of function in the tumor suppressor PATCHED. Activation of GLI1 by EWS/FLI1 gives every indication of being independent of these pathway components and may represent an example of a new mechanism of pathway deregulation in the context of malignancy. Precedent exists for GLI1 deregulation independent of HH and SMO. Knockout mice deficient in SUFU demonstrated a signaling pattern resembling PATCHED1 knockout mice without HH deregulation Figure 6 GLI1 contributes to EWS/FLI1 phenotype in Ewing cellular background. shRNA directed to GLI1 reduces expression of GLI1 and its target PATCHED1 by qPCR (a) with a resultant reduction in anchorage-independent growth (b) with either of two targeting sequences. Data shown are representative of two independent experiments. The Gli-687 experiment was dark-field photographed and the Gli-2757 experiment was transilluminated.
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JP Zwerner et al (Svard et al., 2006) . The phenotype of these mice has features resembling Gorlin's syndrome, the cancerpredisposing condition resulting from PATCHED1 insufficiency in humans. SUFU mutation has been found to be associated with some cases of human medulloblastoma (Taylor et al., 2002) , but these cases are rare (Koch et al., 2004) . These findings serve as a precedent for deregulation of GLI1 in the absence of aberrancy of HH or PATCHED. More recently, GLI1 protein stability has been shown to be another HHindependent pathway deregulation (Di Marcotullio et al., 2006; Huntzicker et al., 2006) . Furthermore, MEK kinase deregulation has been shown to affect GLI1 protein stability and deregulation of this pathway (Lauth et al., 2007) . In the case of our EWS/FLI1 transformation system, we have found no evidence that SUFU expression is altered by EWS/FLI1 and these other potential mechanisms of GLI1 deregulation are under investigation. It is also conceivable that EWS/FLI1 might target GLI1 directly for transcriptional activation. However, transcriptional activation alone might not be sufficient to activate this pathway in NIH3T3 due to a very rapid clearance of GLI1 that has been reported (Huntzicker et al., 2006) . Experiments to address possible indirect effects such as alterations in protein stability are currently underway.
Additional observations in our studies include the deregulation of PDGF-C by HH signaling. Previously, PDGFR-a had been shown to be deregulated by HH signaling but no unregulated ligand was found (Xie et al., 2001 ). These findings demonstrate that PDGF-C may be such an upregulated ligand. We also present data that cMYC is capable of deregulating GLI1 expression and may be involved in EWS/FLI1 deregulation of GLI1. N-MYC has been described as being a target of HH signaling in some contexts but C-MYC has not been implicated in these studies (Kenney et al., 2003; Hatton et al., 2006) . cMYC has been observed to enhance SHH-induced medulloblastoma formation in mice, but the authors of that study found little evidence for concurrent expression of cMYC and SHH and speculated on a paracrine mode of cooperation (Rao et al., 2003) . Our data are the first observation of cMYC expression leading to transcriptional upregulation of GLI1 and PATCHED1. cMYC may play a similar role in EFT, although like others (Smith et al., 2006) , we have not observed that cMYC is consistently a target of EWS/FLI1 in EFT cell lines.
Clearly more extensive studies will be required to determine if our findings will fully translate from EWS/ FLI1-transformed NIH3T3 to an Ewing's tumor cellular background. These studies are ongoing. It is tempting to speculate that a subset of the targets found to be transcriptionally deregulated by EWS/FLI1 may be targeted through a GLI1 intermediate. In NIH3T3, we have shown that both PDGF-C and BMI-1 are upregulated by both EWS/FLI1 and HH-GLI1 signaling, suggesting that EWS/FLI1 targets them through GLI1 deregulation in this cell background. In fact, one recently identified mediator of EWS/FLI1 biologic activity is well known to be a target of HH-GLI1 signaling (Smith et al., 2006) . If such a hypothesis can be proven, we may be able to subclassify some EWS/FLI1 targets as a group targeted through GLI1. Such classification can provide the first steps toward a hierarchical organization of those targets thus far identified. Such a hierarchy can provide a much-needed next level of understanding of the processes of EWS/ FLI1 transformation. It can also further direct efforts toward rationally designed novel therapies for these tumors.
Materials and methods
Northern blots
Northern blots were performed as previously described (May et al., 1993) . The probes for GLI1 and PATCHED1 have been previously described (Bailey et al., 2002) . The b-actin exposures for the blots in Figure 1d have been previously published (Zwerner and May, 2001) .
Retroviral experiments
The generation of recombinant retroviral stocks has been previously described and in these experiments was modified only by using the LINX-A packaging line (Genetica). Retroviral infections and selections have been previously described (May et al., 1993) . These experiments employed either the vector system in that description or pLXIN (Clontech, Mountain View, CA, USA) or the derivative pLXIH vector, which is pLXIN modified by replacement of the neomycin with the hygromycin resistance gene from pTKHYG (Clontech). The retroviral construct for murine SHH and activated SMO was a gift from Dr JM Ruppert. The retroviral construct for murine SUFU was obtained by PCR amplification of the reading frame from the IMAGE clone 6821477. This insert was cloned into pLXIN. Cloning strategy is available on request.
RNAi experiments
The systemic siRNA experiments have been previously described (Hu-Lieskovan et al., 2005a) . pSuper was previously described (Brummelkamp et al., 2002) . The remaining procedures and oligo sequences can be found in the Supplementary Information available online.
Real-time quantitative PCR RNA was isolated using either Tri-Reagent (MRC) or RNeasy Plus Kit (Qiagen, Valencia, CA, USA) according to manufacturer's instructions. CDNAs were prepared from 0.5 mcg total RNA using the Bio-Rad iScript Kit according to manufacturer's instructions. PCR was performed using a Bio-Rad MyiQ Thermal Cycler using Bio-Rad iQ SYBR Green Supermix according to manufacturer's instructions (Bio-Rad, Hercules, CA, USA). Conditions selected were 30 s of denaturation at 94 1C and annealing/extension for 1 min at 60 1C. Data were analysed for expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the comparative C t method with data resulting from the average of three replica wells. Results are reproducible in at least two completely independent experiments. Primers sequences used were (given as sense//antisense, all 5 0 -3 AGAGCTCCTCGAGCTGTTTG// TTCTCTTCCTCGTCGCAGAT Cells, cell culture and materials All tumor cell lines were grown in RPMI supplemented with 2 mM glutamine and 10% fetal bovine serum at 371C and in 5% CO 2 . Parental NIH3T3 cells and those cell lines derived from them were grown in Dulbecco's modified Eagle's medium in 5% bovine calf serum.
Antibodies and immunoblotting
Primary antibodies The GLI1 antiserum employed was Chemicon AB3444.
Secondary antibodies Both the anti-mouse and the anti-rabbit immunoglobulin G-horseradish peroxidase (HRP) antibodies were purchased from Jackson Labs. To perform western blotting, cells were first grown on six-well plates. Upon reaching confluence, cells were lysed in Celytica (SigmaAldrich, Saint Louis, MO, USA). Lysates were then subjected to a few seconds of sonication. After boiling in SDS loading buffer, proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. Membranes were then subjected to 1 h of blocking with 5% nonfat milk in Trisbuffered saline (TBS, 25 mM Tris, 150 mM NaCl, 3 mM KCl, pH 8.0), followed by incubation with an primary antibody diluted in TBS/5% nonfat milk. After 1 h incubation with the primary antibody the membrane was washed four times with TTBS (TBS þ 0.05% Tween 20) and then incubated with a dilution of the appropriate HRP-linked secondary antibody in TBS/5% nonfat milk. After 45 min incubation, the membrane was washed four times with TTBS and then developed with the Pierce SuperSignal Chemiluminescent Substrate per the manufacturer's instructions (Pierce, Rockford, IL, USA). Chemiluminescence was detected at several time points standard autoradiography film (Fuji).
Soft agar transformation assay
Polyclonal, selected populations of the cell type to be analysed were plated in soft agar at either 5000 or 15 000 cells per well of a six-well plate. The agar was made with Iscove's medium containing 10% calf serum for NIH3T3 experiments or 20% fetal calf serum for tumor cell lines as described previously (May et al., 1993) . Agar plates were photographed approximately 2 weeks after plating. Results reported for these assays were consistent over at least two independent assays.
